<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478022</url>
  </required_header>
  <id_info>
    <org_study_id>ISOFEN1</org_study_id>
    <nct_id>NCT01478022</nct_id>
  </id_info>
  <brief_title>To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20</brief_title>
  <acronym>ISOFEN1</acronym>
  <official_title>Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parent Project, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parent Project, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics plasma profile of 3 treatments: ISO 20, IBU 200
      and IBU and ISO combinations (200 +20) given in single dose.

      This study is being conducted to support the submission for new indication in treatment of
      the combinations of Isosorbide Dinitrate and Ibuprofen as a treatment for Duchenne muscular
      dystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed to define drug interactions following the combined administration of
      Isosorbide Dinitrate, a NO donor, and ibuprofen, NSAID, a through pharmacokinetics approach.

      Both ibuprofen and Isosorbide Dinitrate were licensed worldwide. Ibuprofen is approved for
      use in adults and children; Isosorbide is approved for use in adults. Ibuprofen is currently
      used in pediatric patients as a first line anti-inflammatory and antipyretic agent. Consensus
      exists that among NSAIDs ibuprofen is the one endowed with less adverse effects (see note 66
      of the Italian Drug Agency AIFA and MEA). No specific studies concerning safety and
      tolerability of ISDN in pediatric patients have been reported.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: AUC 0-12</measure>
    <time_frame>At period I, II and III with 7 days intervals between periods</time_frame>
    <description>Area under the time-concentration curve (AUC 0-12) of IBU and ISO given concomitantly compared to AUCs of ISO alone and IBU alone. Time points: = at pre dose, 30, 60, 90, 120, 150, 180, 210, 240 min and 5, 6, 8, 10 and 12 hrs post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C max</measure>
    <time_frame>At period I, II and III with 7 days intervals between periods</time_frame>
    <description>C max of IBU and ISO given concomitantly compared to AUCs of ISO alone and IBU alone. Time points: = at pre dose, 30, 60, 90, 120, 150, 180, 210, 240 min and 5, 6, 8, 10 and 12 hrs post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T max</measure>
    <time_frame>At period I, II and III with 7 days intervals beteween periods</time_frame>
    <description>T max of IBU and ISO given concomitantly compared to AUCs of ISO alone and IBU alone. Time points: = at pre dose, 30, 60, 90, 120, 150, 180, 210, 240 min and 5, 6, 8, 10 and 12 hrs post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>9 days</time_frame>
    <description>Adverse Events registration At visit 2, visit 3 and visit 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>9 days</time_frame>
    <description>Pulse rate and blood pressure (Diastolic and Systolic) measurements in sitting position at pre-dose, and 1 and 3 hours after study drug intake. Complete physical examination At visit 2, visit 3 and visit 4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Duchenne Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>Isosorbide Dinitrate 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide Dinitrate 10 mg b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 200 mg daily, capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide dinitrate and Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Dinitrate</intervention_name>
    <description>Isosorbide Dinitrate 10 mgx2, daily, capsules</description>
    <arm_group_label>Isosorbide Dinitrate 20 mg</arm_group_label>
    <other_name>Diniket 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 200 mg daily, capsules</description>
    <arm_group_label>Ibuprofen 200 mg</arm_group_label>
    <other_name>Antalgil 200 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ibuprofen and Isosorbide Dinitrate combination</intervention_name>
    <description>Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose</description>
    <arm_group_label>Isosorbide dinitrate and Ibuprofen</arm_group_label>
    <other_name>Antalgil 200 mg and Diniket 10 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy free-living

          -  Males between the age of 18 and 27

          -  Normal ECG

          -  Body Mass Index of 19.0-29.0 (Kg/m2)

          -  Subject healthy in the opinion of the Investigator

          -  Signed informed consent after verbal and written information

        Exclusion Criteria:

          -  Clinically significant underlying systemic illness that may preclude the subject's
             ability to complete the trial

          -  Any Gastrointestinal conditions which, in the opinion of the Investigator, may
             interfere with the absorption of the drug or render the subjects unable to take oral
             medication (gastric ulcer, peptic ulcer, stomach acid, frequent diarrhea,
             gastrointestinal surgery)

          -  History of the following cardiac diseases SBP &lt;120 mmHG or DBP &lt; 80 mmHg

          -  Platelet count &lt; 100000/mm3

          -  History of recurrent headache

          -  History of ongoing or clinically relevant glaucoma

          -  History of alcohol, drug or medication abuse within the past 2 years

          -  Treatment with norepinephrine, acetylcholine and histamine

          -  History or presence of allergy or intolerance to the study drugs or their components
             or drugs of their class, or a history of drug or other allergy that, in the opinion of
             the physician responsible, contraindicates their participation

          -  Participation in another study phase 1 with any investigational product within 6
             months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>27 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Clementi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luigi Sacco Hospital - Phase I Department - Via G. B. Grassi 74 20157 Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilio Clementi, PhD</last_name>
    <phone>39.02.50319621</phone>
    <email>emilio.clementi@unimi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianca Francucci, M.D.</last_name>
    <phone>39.02.50319621</phone>
    <email>francucci.bianca@hsacco.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Phase 1 Unit - Luigi Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Clementi, PhD</last_name>
      <phone>39.02.50319621</phone>
      <email>emilio.clementi@unimi.it</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Francucci, M.D.</last_name>
      <phone>39.02.50319621</phone>
      <email>francucci.bianca@hsacco.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Duchenne</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

